CMPX
NASDAQCompass Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)
Price$5.21-0.11 (-1.98%)
01:30 PM07:45 PM
News · 26 weeks45-100%
2025-10-262026-04-19
Mix890d
- SEC Filings3(38%)
- Other2(25%)
- Insider1(13%)
- Analyst1(13%)
- Offering1(13%)
Latest news
25 items- SECSEC Form S-8 filed by Compass Therapeutics Inc.S-8 - Compass Therapeutics, Inc. (0001738021) (Filer)
- SECSEC Form 10-K filed by Compass Therapeutics Inc.10-K - Compass Therapeutics, Inc. (0001738021) (Filer)
- SECCompass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
- PRCompass Therapeutics Reports 2025 Financial Results and Provides Corporate UpdateIn the Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer, the prespecified event threshold of 80% overall survival (OS) events was reached in Q1 2026; as a result, the analyses of progression-free survival (PFS) and OS are expected to be reported in April. Based on previously reported responses in patients with triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) in the Phase 1 study of CTX-8371 (PD-1 x PD-L1 bispecific antibody), expansion cohorts are now open and enrolling patients with these tumor types; based on an additional response in a patient with Hodgkin lymphoma, a further expansion cohort of
- PRBiliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsightLAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Compass Therapeutics Inc.SCHEDULE 13G/A - Compass Therapeutics, Inc. (0001738021) (Subject)
- ANALYSTCraig Hallum initiated coverage on Compass Therapeutics with a new price targetCraig Hallum initiated coverage of Compass Therapeutics with a rating of Buy and set a new price target of $15.00
- INSIDERCHIEF EXECUTIVE OFFICER Schuetz Thomas J. covered exercise/tax liability with 36,687 shares, decreasing direct ownership by 0.55% to 6,603,336 units (SEC Form 4)4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- PRThe $185B Cancer Surge: Why the FDA's Fast-Track Pivot is Scaling a New Immunotherapy EraVANCOUVER, British Columbia, Jan. 14, 2026 (GLOBE NEWSWIRE) -- USANewsGroup.com News Commentary – The global immuno-oncology market is set to explode from its current $35 billion level to a massive $185.69 billion by 2035 as the industry moves toward the coordinated activation of the immune system[1]. This surge is being accelerated by the $69.16 billion genomics revolution, which is now integrating advanced profiling into every oncology workflow to pick winning treatments[2]. This strategic push for registration-ready precision assets fuels the 2026 investment case for Oncolytics Biotech Inc. (NASDAQ:ONCY), ImmunityBio (NASDAQ:IBRX), OS Therapies (NYSE-A: OSTX), BioNTech SE (NASDAQ:BNTX),
- INSIDERCHIEF EXECUTIVE OFFICER Schuetz Thomas J. covered exercise/tax liability with 46,777 shares, decreasing direct ownership by 0.70% to 6,640,023 units (SEC Form 4)4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- SECSEC Form EFFECT filed by Compass Therapeutics Inc.EFFECT - Compass Therapeutics, Inc. (0001738021) (Filer)
- SECCompass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events, Financial Statements and Exhibits8-K - Compass Therapeutics, Inc. (0001738021) (Filer)
- INSIDERCFO Shin Barry was granted 125,000 shares, increasing direct ownership by 31% to 525,000 units (SEC Form 4)4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERSEC Form 4 filed by Chief Medical Officer Sirard Cynthia4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERCEO Schuetz Thomas J. was granted 250,000 shares, increasing direct ownership by 4% to 6,686,800 units (SEC Form 4)4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERSEC Form 4 filed by Chief Commercial Officer Prasad Arjun4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERSEC Form 4 filed by Director Lindahl Richard S4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERChief Accounting Officer Lerner Neil was granted 62,500 shares, increasing direct ownership by 20% to 382,500 units (SEC Form 4)4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERSEC Form 4 filed by Director Chiniara Ellen4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERSEC Form 4 filed by Director Gray Mary Ann4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERSEC Form 4 filed by Director Boylan James P4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERSEC Form 4 filed by Director Gordon Carl L4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERSEC Form 4 filed by Director Ferneau Philip4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERGeneral Counsel Anderman Jonathan was granted 150,000 shares, increasing direct ownership by 714% to 171,000 units (SEC Form 4)4 - Compass Therapeutics, Inc. (0001738021) (Issuer)
- INSIDERSEC Form 3 filed by new insider Sirard Cynthia3 - Compass Therapeutics, Inc. (0001738021) (Issuer)